phenyl 3-(benzyloxy)-2,6-dibromo-5-methylisonicotinate | 1254367-40-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: phenyl 3-(benzyloxy)-2,6-dibromo-5-methylisonicotinate
• 英文别名: Phenyl 2,6-dibromo-3-methyl-5-phenylmethoxypyridine-4-carboxylate
• CAS: 1254367-40-2
• 化学式: C₂₀H₁₅Br₂NO₃
• 分子量: 477.152
• InChiKey: KSCAPHJNSXKOEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  phenyl 3-(benzyloxy)-2,6-dibromo-5-methylisonicotinate 在 盐酸 、 4-二甲氨基吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.17h， 生成 (4aS,11aR,12aS,13S)-8-amino-3,7-bis(benzyloxy)-4a-((tert-butyldimethylsilyl)oxy)-10,13-bis(dimethylamino)-5-hydroxy-11a,12,12a,13-tetrahydroisoxazolo[5',4':6,7]naphtho[2,3-g]isoquinoline-4,6(4aH,11H)-dione
  参考文献：
  名称：

  8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents

  摘要：

  A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.

  DOI：

  10.1021/jm1015389
• 作为产物：
  描述：

  3-(benzyloxy)-5-chloroisonicotinic acid 在 4-二甲氨基吡啶 、 双(三环己基膦)二氯化钯 、 anhydrous dipotassium phosphate 、 草酰氯 、 双氧水 、 三乙胺 、 N,N-二甲基甲酰胺 、 三溴氧磷 作用下， 以 二氯甲烷 、 水 、 溶剂黄146 、 甲苯 为溶剂， 反应 24.25h， 生成 phenyl 3-(benzyloxy)-2,6-dibromo-5-methylisonicotinate
  参考文献：
  名称：

  8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents

  摘要：

  A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.

  DOI：

  10.1021/jm1015389

文献信息

• [EN] 8-AZA TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE 8-AZA TÉTRACYCLINE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010129055A1

  公开（公告）日：2010-11-11

  The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式（I）表示的化合物或其药用盐。结构式I的变量在此定义。还描述了包括结构式I化合物的药物组合物及其治疗用途。
• 8-AZA Tetracycline Compounds
  申请人：Clark Roger B.

  公开号：US20120108569A1

  公开（公告）日：2012-05-03

  The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
• US8367654B2
  申请人：——

  公开号：US8367654B2

  公开（公告）日：2013-02-05
• US8828988B2
  申请人：——

  公开号：US8828988B2

  公开（公告）日：2014-09-09
• 8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents
  作者：Roger B. Clark、Minsheng He、Corey Fyfe、Denene Lofland、William J. O’Brien、Louis Plamondon、Joyce A. Sutcliffe、Xiao-Yi Xiao

  DOI：10.1021/jm1015389

  日期：2011.3.10

  A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.